Livalo
Livalo (pitavastatin) is an HMG-CoA reductase inhibitor (statin) that works by inhibiting the enzyme responsible for cholesterol production in the liver. By lowering LDL ('bad') cholesterol and triglycerides while raising HDL ('good') cholesterol, it helps reduce the risk of cardiovascular events such as heart attacks and strokes.
Dosage by Body Weight
The standard starting dosage for adults is 2 mg taken orally once daily, with or without food. The maximum recommended dose is 4 mg once daily. For pediatric patients aged 8 years and older, the recommended starting dose is 1 mg or 2 mg once daily, up to a maximum of 2 mg once daily. Dosage adjustments are required for patients with moderate to severe renal impairment.
- Body Weight
- Below 5 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness have not been established in pediatric patients under 8 years of age.
- Body Weight
- 5-7 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness have not been established in pediatric patients under 8 years of age.
- Body Weight
- 8-10 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness have not been established in pediatric patients under 8 years of age.
- Body Weight
- 11-15 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness have not been established in pediatric patients under 8 years of age.
- Body Weight
- 16-20 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness have not been established in pediatric patients under 8 years of age.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Not recommended | N/A | Safety and effectiveness have not been established in pediatric patients under 8 years of age. |
| 5-7 kg | Not recommended | N/A | Safety and effectiveness have not been established in pediatric patients under 8 years of age. |
| 8-10 kg | Not recommended | N/A | Safety and effectiveness have not been established in pediatric patients under 8 years of age. |
| 11-15 kg | Not recommended | N/A | Safety and effectiveness have not been established in pediatric patients under 8 years of age. |
| 16-20 kg | Not recommended | N/A | Safety and effectiveness have not been established in pediatric patients under 8 years of age. |
Formulation
Purpose
Used in conjunction with dietary modification to reduce elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (ApoB), and triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C) in adults and pediatric patients aged 8 years and older with primary hyperlipidemia or mixed dyslipidemia.
Generic Name
PitavastatinScheduled Drug
Yes. This medicine should be supplied or used only according to applicable prescription and regulatory requirements.